

Elizabeth W Loder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7899628/publications.pdf>

Version: 2024-02-01

107
papers

46,188
citations

94433

37
h-index

49909

87
g-index

111
all docs

111
docs citations

111
times ranked

28867
citing authors

#	ARTICLE	IF	CITATIONS
1	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, The, 2021, 372, n71.	6.0	26,066
2	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews, 2021, 10, 89.	5.3	3,624
3	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. International Journal of Surgery, 2021, 88, 105906.	2.7	3,487
4	PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ, The, 2021, 372, n160.	6.0	3,413
5	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€”Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250.	0.3	1,657
6	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Medicine, 2021, 18, e1003583.	8.4	1,340
7	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, 2021, 134, 178-189.	5.0	995
8	Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization. JAMA - Journal of the American Medical Association, 2021, 326, 1614.	7.4	829
9	Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ, The, 2021, 375, n2233.	6.0	408
10	The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies. Headache, 2015, 55, 21-34.	3.9	405
11	Declaraci3n PRISMA 2020: una guÃa actualizada para la publicaci3n de revisiones sistemÃticas. Revista Espanola De CardiologÃa (English Ed), 2021, 74, 790-799.	0.6	333
12	The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache, 2018, 58, 496-505.	3.9	330
13	The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies. Headache, 2013, 53, 427-436.	3.9	319
14	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9.	0.3	254
15	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31.	0.3	251
16	Triptan Therapy in Migraine. New England Journal of Medicine, 2010, 363, 63-70.	27.0	178
17	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2016, 56, 821-834.	3.9	160
18	Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. Headache, 2013, 53, 1651-1659.	3.9	150

#	ARTICLE	IF	CITATIONS
19	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMJ</i> , The, 2022, 376, e067975.	6.0	141
20	The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. <i>Headache</i> , 2021, 61, 60-68.	3.9	119
21	Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine. <i>JAMA Internal Medicine</i> , 2021, 181, 317.	5.1	87
22	The Prevalence, Burden, and Treatment of Severe, Frequent, and Migraine Headaches in <sc>US</sc> Minority Populations: Statistics From National Survey Studies. <i>Headache</i> , 2015, 55, 214-228.	3.9	82
23	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 636-649.	1.3	81
24	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e13.	0.5	78
25	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Medicine</i> , 2022, 20, 23.	5.5	73
26	Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. <i>Headache</i> , 2018, 58, 5-21.	3.9	65
27	Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. <i>JAMA Neurology</i> , 2018, 75, 566.	9.0	64
28	Safety of Sumatriptan in Pregnancy. <i>CNS Drugs</i> , 2003, 17, 1-7.	5.9	62
29	General Principles of Migraine Management: The Changing Role of Prevention. <i>Headache</i> , 2005, 45, S33-S47.	3.9	61
30	Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. <i>Cephalalgia</i> , 2020, 40, 1511-1522.	3.9	61
31	Medication overuse headache. <i>Neurology</i> , 2017, 89, 1296-1304.	1.1	58
32	Tension-type headache. <i>BMJ: British Medical Journal</i> , 2008, 336, 88-92.	2.3	52
33	Pravila PRISMA 2020.. <i>Medicina Fluminensis</i> , 2021, 57, 444-465.	0.3	50
34	Use of Botulinum Toxins for Chronic Headaches: A Focused Review. <i>Clinical Journal of Pain</i> , 2002, 18, S169-S176.	1.9	47
35	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. <i>Cephalalgia</i> , 2016, 36, 358-370.	3.9	45
36	The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?. <i>Headache</i> , 2019, 59, 113-117.	3.9	45

#	ARTICLE	IF	CITATIONS
37	Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. Headache, 2018, 58, 218-229.	3.9	41
38	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics, 2022, 40, 601-609.	3.3	39
39	Hormonal Management of Migraine Associated With Menses and the Menopause: A Clinical Review.. Headache, 2007, 47, 329-340.	3.9	38
40	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache, 2016, 56, 725-740.	3.9	38
41	Pain-free rates with zolmitriptan 2.5â€‰mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Current Medical Research and Opinion, 2005, 21, 381-389.	1.9	35
42	Offâ€Label Prescribing of Drugs in Specialty Headache Practice. Headache, 2004, 44, 636-641.	3.9	29
43	Naratriptan in the Prophylaxis of Cluster Headache. Headache, 2002, 42, 56-57.	3.9	28
44	Who Should Try New Antibody Treatments for Migraine?. JAMA Neurology, 2018, 75, 1039.	9.0	24
45	Fixed Drug Combinations for the Acute Treatment of Migraine. CNS Drugs, 2005, 19, 769-784.	5.9	23
46	Registration status and outcome reporting of trials published in core headache medicine journals. Neurology, 2015, 85, 1789-1794.	1.1	23
47	Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice: A Retrospective Cohort Study. Headache, 2016, 56, 1626-1634.	3.9	23
48	Awareness, usage and perceptions of authorship guidelines: an international survey of biomedical authors. BMJ Open, 2020, 10, e036899.	1.9	23
49	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clinical Therapeutics, 2022, 44, 158-168.	2.5	22
50	The comorbidity burden of patients with cluster headache: a population-based study. Journal of Headache and Pain, 2017, 18, 76.	6.0	21
51	Evaluation for Secondary Causes of Headache: The Role of Blood and Urine Testing. Headache, 2011, 51, 338-345.	3.9	19
52	Underrepresentation of Women Among Authors of Invited Commentaries in Medical Journalsâ€Where Are the Female Editorialists?. JAMA Network Open, 2019, 2, e1913665.	5.9	19
53	Workforce Gap Analysis in the Field of Headache Medicine in the United States. Headache, 2020, 60, 478-481.	3.9	19
54	Menstrual Migraine: Pathophysiology, Diagnosis, and Impact. Headache, 2006, 46, S55-S60.	3.9	18

#	ARTICLE	IF	CITATIONS
55	Volume and Nature of Telephone Calls in a Specialty Headache Practice. <i>Headache</i> , 2002, 42, 883-887.	3.9	16
56	Monoclonal Antibodies for Migraine Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1985.	7.4	14
57	Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review. <i>Cephalalgia</i> , 2021, 41, 760-773.	3.9	13
58	Biomedical authors' awareness of publication ethics: an international survey. <i>BMJ Open</i> , 2018, 8, e021282.	1.9	12
59	Ten Eleven Things Not to Say to Your Female Colleagues. <i>Headache</i> , 2019, 59, 1846-1854.	3.9	12
60	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 213.	2.1	12
61	Headache Attributed to Psychiatric Disorder: A Case Series. <i>Psychosomatics</i> , 2005, 46, 326-333.	2.5	9
62	Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. <i>Headache</i> , 2018, 58, 1639-1657.	3.9	9
63	Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board. <i>Headache</i> , 2020, 60, 1000-1004.	3.9	9
64	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. <i>Journal of Medical Economics</i> , 2022, 25, 1-7.	2.1	9
65	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>European Journal of Health Economics</i> , 2022, 23, 1309-1317.	2.8	9
66	Validity of cluster headache diagnoses in an electronic health record data repository. <i>Headache</i> , 2016, 56, 1132-1136.	3.9	8
67	Migraine Pain Location and Measures of Healthcare Use and Distress: An Observational Study. <i>Pain Research and Management</i> , 2018, 2018, 1-11.	1.8	8
68	Part II: Clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. <i>Current Medical Research and Opinion</i> , 2005, 21, S8-S12.	1.9	7
69	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. <i>BMC Public Health</i> , 2022, 22, 179.	2.9	7
70	Prophylaxis: Headaches That Never Happen. <i>Headache</i> , 2008, 48, 694-696.	3.9	6
71	Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. <i>JAMA Internal Medicine</i> , 2019, 179, 421.	5.1	6
72	Medication overuse headache: The trouble with prevalence estimates. <i>Cephalalgia</i> , 2020, 40, 3-5.	3.9	5

#	ARTICLE	IF	CITATIONS
73	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. Headache, 2020, 60, 1837-1845.	3.9	5
74	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114.	2.2	5
75	Guidance relevant to the reporting of health equity in observational research: a scoping review protocol. BMJ Open, 2022, 12, e056875.	1.9	5
76	Adding NSAIDs to triptans: Could less be more?. Cephalalgia, 2014, 34, 407-408.	3.9	4
77	Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies. Headache, 2017, 57, 1243-1251.	3.9	4
78	Disentangling placebo effects in the treatment of migraine. Nature Reviews Neurology, 2020, 16, 657-658.	10.1	4
79	A Pilot Study of Pain and Attitudes Toward Pain in a Rehabilitation Population. Pain Medicine, 2002, 3, 333-338.	1.9	3
80	Consideration of Costs and Open-Label Studies of Erenumab—Reply. JAMA Neurology, 2019, 76, 236.	9.0	3
81	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 146-155.	0.9	3
82	Migraine diagnosis and treatment. Primary Care - Clinics in Office Practice, 2004, 31, 277-292.	1.6	2
83	The approach to the difficult patient. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 233-238.	1.8	2
84	Headache Rounds: Sudden, Transient Neurologic Symptoms in a Woman With Migraine. Headache, 2015, 55, 1274-1282.	3.9	2
85	Potential Benefits of Migraine—What Is It Good For?. JAMA Neurology, 2019, 76, 250.	9.0	2
86	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. F1000Research, 2021, 10, 455.	1.6	2
87	Characteristics of Neuropsychiatric Mobile Health Trials: Cross-Sectional Analysis of Studies Registered on ClinicalTrials.gov. JMIR MHealth and UHealth, 2020, 8, e16180.	3.7	1
88	Who Will Prescribe? A Proposal for Specialized Opioid Management Clinics. Pain Practice, 2003, 3, 218-221.	1.9	0
89	Conclusion: How primary care physicians can help their patients with migraine. The American Journal of Medicine: Supplement, 2005, 118, 45-46.	1.6	0
90	Mistaking primary headache for another condition. , 0, , 20-37.		0

#	ARTICLE	IF	CITATIONS
91	When historical or examination findings are missed or misinterpreted. , 0, , 84-99.		0
92	Medicolegal pitfalls in headache management. , 0, , 175-185.		0
93	Missing dangerous causes of headache. , 0, , 38-53.		0
94	Pitfalls in diagnostic testing: imaging and lumbar puncture. , 0, , 54-72.		0
95	Errors in management of acute headache. , 0, , 100-118.		0
96	Pitfalls in diagnostic testing: blood, urine, and other tests. , 0, , 73-83.		0
97	Pitfalls in drug therapy to prevent headaches. , 0, , 119-144.		0
98	Pitfalls in nonpharmacologic treatment of headache. , 0, , 145-161.		0
99	Challenges and special situations in headache management. , 0, , 162-174.		0
100	Confusing one benign headache with another. , 0, , 1-19.		0
101	Further Questioning of the Significance of the Gepants: A Response. Headache, 2019, 59, 1831-1831.	3.9	0
102	Timeâ€™s up for he and him as the default pronouns for doctors. BMJ, The, 2019, 367, l6565.	6.0	0
103	Ten (No, Make that 11) Ways the Migraine Mavens Have Changed the Conversation About Sexism in Medicine. Headache, 2020, 60, 1042-1046.	3.9	0
104	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.9	0
105	Equal Pay for Women Neurologists. Neurology, 2022, 98, 347-348.	1.1	0
106	Review: several drugs, especially triptans, are effective for pain relief in acute migraine. ACP Journal Club, 2002, 137, 103.	0.1	0
107	Review: Several drugs, especially triptans, are effective for pain relief in acute migraine. ACP Journal Club, 2002, 137, 103.	0.1	0